MedTrace Logo

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

NCT06934889 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-14

No results posted yet for this study

Summary

The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.

Conditions

Interventions

DRUG

ERAS-801

will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.

DRUG

ABBV-637

will be administered intravenously over one hour (+/- 10 min) once every 28 days on the first day of the new cycle.

DRUG

ABBV-155

will be administered intravenously over at least 30 minutes once every 21 days on the first day of the new cycle.

DRUG

Temozolomide

Temozolomide will be continued for 6 cycles after radiation.

RADIATION

Radiotherapy

will be given as per standard of care radiation for GBM

Sponsors & Collaborators

Principal Investigators

  • Thomas Kaley, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2028-04-30
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06934889 on ClinicalTrials.gov